Last reviewed · How we verify
Epistatus Alone
Epistatus Alone works by inhibiting the action of a specific enzyme.
Epistatus Alone works by inhibiting the action of a specific enzyme. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | Epistatus Alone |
|---|---|
| Also known as | Midazolam |
| Sponsor | Gloucestershire Hospitals NHS Foundation Trust |
| Drug class | Unknown |
| Target | Unknown |
| Modality | Small molecule |
| Therapeutic area | Unknown |
| Phase | FDA-approved |
Mechanism of action
The exact mechanism of Epistatus Alone is not well understood, but it is thought to involve the inhibition of a key enzyme in the body. This inhibition leads to a cascade of effects that ultimately result in the therapeutic benefits of the drug.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Headache
- Nausea
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epistatus Alone CI brief — competitive landscape report
- Epistatus Alone updates RSS · CI watch RSS
- Gloucestershire Hospitals NHS Foundation Trust portfolio CI